Please feel free to forward to fellow researchers and share news of our journal | Dear Colleague, We are delighted to announce the publication of Volume 5, Issue 3 of our Kidney Cancer journal. This issue includes two research articles, an article commentary, and two systematic reviews. From the editor of our regular journal section, there is also a new Clinical Trials Corner contribution. View all the open access content via the links below.. | Call for Papers As a member of our community, we would like to invite you to submit your own research articles to the journal, which offers contributing authors many benefits: • First class Editorial Board • Rigorous peer review and speedy manuscript processing • Rapid online publication (pre-press) on acceptance • The first volumes of the journal freely available to all readers • Articles accepted this year will be published open access with no article processing fee Submit your manuscript online via Editorial Manager View detailed Instructions to Authors Aims and Scope Kidney Cancer is an international, multidisciplinary journal that provides an invaluable and indispensable platform for the many collaborative, transdisciplinary, and translational efforts to help treat and finally cure this malignancy. Best wishes, Primo N. Lara Jr, MD UC Davis Comprehensive Cancer Center Sacramento, CA, USA Email: kca@iospress.com Peter Mulders, MD, PhD Radboud UMC Nijmegen, The Netherlands Email: kca@iospress.com Editors-in-Chief Sign up now for Kidney Cancer news Join the conversation at: twitter.com/KCA_Journal | All articles are freely available online for all to read, download and share. RESEARCH ARTICLES Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States Wilson, Lauren E. | Spees, Lisa | Pritchard, Jessica | Greiner, Melissa A. | Scales Jr, Charles D. | Baggett, Christopher D. | Kaye, Deborah | George, Daniel J. | Zhang, Tian | et al. Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma Bhindi, Bimal | Bearrick, Elizabeth N. | Cheville, John C. | Lohse, Christine M. | Mason, Ross J. | Shah, Paras | Harrington, Susan | Zhang, Henan | Dong, Haidong | Boorjian, Stephen A. | et al. ARTICLE COMMENTARY Defining the Optimal Management Strategy for Small Renal Masses Dall’Era, Marc | Lara Jr., Primo N. SYSTEMATIC REVIEWS Active Surveillance of Small Renal Masses: A Systematic Review Ellis, Elizabeth E. | Messing, Edward First-Line Immunotherapy Combinations in Advanced Renal Cell Carcinoma: A Rapid Review and Meta-Analysis Shpilsky, Jason | Catalano, Paul J. | McDermott, David F. OTHER CONTENT Clinical Trials Corner: Contact After the First Round Parikh, Mamta | Kidney Cancer Indexing News | We are pleased to announce that, since earlier this year, KCA is covered in the Emerging Sciences Citation Index (ESCI) category in the Web of Science. This is a significant step, as ESCI journals that gain impact move to the Science Citation Index-Expanded, which is the citation database that generates impact factors. In addition, we are very pleased to announce that the journal is also now covered in Scopus. | Most Viewed Kidney Cancer Articles in Q3 2021 Listing articles published in 2020 and 2021 so you can read the most popular recent content Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic (Research Article in Vol.5, Iss.2, 2021) Salgia, Sabrina | Salgia, Nicholas | Prajapati, Sweta | Seghal, Ishaan | Bautista, Frank | Ruel, Nora | Salgia, Meghan | Salgia, Deborah A. | Salgia, Ravi | Pal, Sumanta K. Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions (Review Article in Vol.5, Iss.1, 2021) Kazarian, Austin G. | Chawla, Neal S. | Muddasani, Ramya | Pal, Sumanta K. Renal Cell Carcinoma with Inferior Vena Cava Extension: Can Classification Be Optimized to Predict Perioperative Outcomes? (Short Communication in Vol.4, Iss.2, 2020) Leibovich, Bradley C. | Lohse, Christine M. | Cheville, John C. | Potretzke, Theodora A. | Tsivian, Matvey | Shah, Paras H. | Boorjian, Stephen A. | Thompson, R. Houston | Lyon, Timothy D. Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma (Review Article, Vol.5, Iss.2, 2021) Tsimafeyeu, Ilya PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review (Systematic Review in Vol.5, Iss.2, 2021) Dias Carneiro, André Paternò Castello | Marques Monteiro, Fernando Sabino | Soares, Andrey | Kidney Cancer Association News Austin, TX | Nov 5 & 6, 2021 | In-Person & Virtual The Kidney Cancer Association is pleased to announce the International Kidney Cancer Symposium (IKCS) will be held in Austin, TX in November and will be welcoming delegates in-person and virtually. It is an opportunity for physicians, researchers, academics, and industry professionals from across the globe to join together and exchange ideas which will direct the future of kidney cancer research and treatment in the ultimate pursuit of a cure. The IKCS event takes place across two days, on November 5 and 6, 2021. There will be 50+ experts presenting over the course of the conference covering the topics listed below, and more. Topics: * The Role of Perioperative Therapy in RCC * Multimodality Perspectives on Clinical Trial Development * Non-clear cell RCC * Translational Cancer Insights * Mentoring the Next Generation and Networking * Impact of Adjuvant IO on 1st Line Therapy * Legislative Advocacy, Funding, and the Patient Experience | Attendees are eligible for CME credits up to 13.25 AMA PRA Category 1 Credit(s) | Registration is open: Book your place via the IKCS website. Register now! | Please Share Kidney Cancer News With Your Colleagues Help Spread the News! | If you know of any colleagues or fellow researchers who are not yet signed up to receive the newsletter, we invite you to share this mailing with them. Click on the visual or access the sign-up link here. Kidney Cancer has an active social media presence. If you are not yet interacting with the journal on social media, why not take the time today to follow us on Twitter? Be part of the discussion! | You are receiving this mailing as you are signed up to receive news from KCA. You can unsubscibe or alter your preferences at any time by clicking the links below. | |